Skip to main content

March 2015, Vol 8, Sixth Annual Payers' Guide

FDA Approvals, Payers' Guide
The Sixth Annual Payers’ Guide to New FDA Approvals
Read More
Payers' Guide
New FDA Drug Approvals Hit an 18-Year High in 2014
Gary M. Owens, MD
Read More
Drug Updates, Payers' Guide
FDA Approvals of Brand-Name Prescription Drugs in 2014
Read More
Drug Updates, Payers' Guide
Afrezza (Insulin Human) Inhalation Powder Approved for the Treatment of Patients with Type 1 or Type 2 Diabetes
Loretta Fala
Read More
Drug Updates, Payers' Guide
Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Lisa A. Raedler, PhD, RPh
Read More
Drug Updates, Payers' Guide
Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non–Small-Cell Lung Cancer
Loretta Fala
Read More
Drug Updates, Payers' Guide
Once-a-Day Harvoni (Ledipasvir plus Sofosbuvir), a New Oral Combination for the Treament of Patients with Genotype 1 Chronic Hepatitis C Infection
Lisa A. Raedler, PhD, RPh
Read More
Drug Updates, Payers' Guide
Imbruvica (Ibrutinib), First-in-Class Bruton’s Tyrosine Kinase Inhibitor, Receives Expanded Indications for Patients with Relapsed Chronic Lymphocytic Leukemia
Lisa A. Raedler, PhD, RPh
Read More
Drug Updates, Payers' Guide
Invokamet (Canagliflozin plus Metformin HCl): First Fixed-Dose Combination with an SGLT2 Inhibitor Approved for the Treatment of Patients with Type 2 Diabetes
Loretta Fala
Read More
Drug Updates, Payers' Guide
Jakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera
Lisa A. Raedler, PhD, RPh
Read More
Page 1 of 3
Results 1 - 10 of 27